Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03020030
Recruitment Status : Recruiting
First Posted : January 13, 2017
Last Update Posted : May 27, 2019
Sponsor:
Collaborator:
Servier
Information provided by (Responsible Party):
Lewis B. Silverman, M.D., Dana-Farber Cancer Institute

Brief Summary:

Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous lymphocytes are called lymphoblasts. They do not help fight infection and crowd out the normal blood cells in the bone marrow so that the body cannot make enough normal blood cells. ALL is always fatal if it is not treated. With current treatments, most children and adolescents with this disease will be cured.

The standard treatment for ALL involves about 2 years of chemotherapy. The drugs that are used, and the doses of the drugs, are similar but not identical for all children and adolescents with ALL. Some children and adolescents receive stronger treatment, especially during the first several months. A number of factors are used to decide how strong the treatment should be to give the best chance for cure. These factors are called "risk factors". This trial is studying the use of a new, updated set of risk factors to decide how strong the treatment will be. The study also will test a new way of dosing a chemotherapy drug called pegaspargase (which is part of the standard treatment for ALL) based on checking levels of the drug in the blood and adjusting the dose based on the levels.


Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia, Pediatric Drug: Pegaspargase Drug: Erwinia asparaginase Drug: Cyclophosphamide Drug: CYTARABINE Drug: DASATINIB Drug: DEXAMETHASONE Drug: Dexrazoxane Drug: Doxorubicin Drug: ETOPOSIDE Drug: HYDROCORTISONE Drug: LEUCOVORIN CALCIUM Drug: MERCAPTOPURINE Drug: METHOTREXATE Drug: NELARABINE Drug: Vincristine Phase 3

Detailed Description:

There are a standard set of risk factors which are used to decide how strong treatment should be for a child with ALL. These risk factors include the child's age when the leukemia is diagnosed, how high the white blood cell count (WBC) is in the blood, whether or not leukemia cells are seen in the spinal fluid (referred to as Central Nervous System or CNS status), and whether or not the leukemia has certain abnormalities in their chromosomes (genetic material in the cell). Another risk factor is the amount of leukemia in the marrow that can be measured by a special laboratory test called "MRD" (Minimal Residual Disease) after the first month of treatment.

Over the last several years, new factors have been identified which help predict how well a child's leukemia may respond to treatment. These new risk factors include additional abnormalities in the genes of the leukemia cell, as well the amount of leukemia (MRD level) at second time point (about 2-3 months after starting treatment).

In this trial, the investigators will use the new risk factors along with old risk factors to decide how strong the treatment will be. The goal is to better identify those participants who might benefit from stronger treatment in order to improve their chance for cure. The investigators also hope to better identify participants who have a high chance of being cured with standard treatment in order to reduce their chance of side effects while maintaining the chance of cure.

This trial also aims to study the dosing of a drug called pegaspargase. Pegaspargase is a chemotherapy drug that is an important part of ALL treatment but it is also can cause many side effects. With the standard dose of pegaspargase, levels of the drug in the blood are higher than may be necessary to effectively treat leukemia.

On this research study, the investigators will be comparing the standard dose of pegaspargase with a new way of dosing the drug based on levels of the drug that we can measure in the blood. With the new way of doing, treatment will begin with a lower dose. If the levels are high, the dose will be decreased one more time; however, if at any time the levels are too low, dosing will be switched back up to the standard dose. The goal of this research study is to learn whether this new way of dosing (starting at a lower dose and changing the dose based on drug levels in the blood) will decrease side effects but still be as effective as the standard dosing of the drug.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Actual Study Start Date : March 3, 2017
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2026


Arm Intervention/treatment
Initial Low Risk (Initial LR)

Meets all the following criteria: B-ALL, Age 1-<15 years, WBC < 50,000/microliter, CNS-1 or CNS-2, no BCR-ABL1, no iAMP21, and no VHR characteristics.

Treated with Induction IA (vincristine, dexamethasone, pegaspargase), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA.

Drug: Pegaspargase
Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization

Drug: Erwinia asparaginase
Only for patients with Pegaspargase allergy or silent inactivation.
Other Names:
  • ERWINAZE®
  • ERWINIA CHRYSANTHEMI
  • ERWINASE®

Drug: Cyclophosphamide
Standard of Care
Other Name: CYTOXAN

Drug: CYTARABINE
Standard of Care
Other Names:
  • CYTOSINE ARABINOSIDE
  • ARA-C
  • CYTOSAR®

Drug: DEXAMETHASONE
Standard of Care
Other Names:
  • DECADRON®
  • HEXADROL®,
  • DEXONE®,
  • DEXAMETH®

Drug: HYDROCORTISONE
Standard of Care

Drug: LEUCOVORIN CALCIUM
Standard of Care

Drug: MERCAPTOPURINE
Standard of Care
Other Name: 6-MP

Drug: METHOTREXATE
Standard of Care

Drug: Vincristine
Standard of Care
Other Name: Oncovin

Initial High Risk (Initial HR)

Meets at least one of the following criteria: Age >=15 years, WBC >=50,000/microliter, CNS-3, T-ALL, iAMP21, BCR-ABL1

And: No VHR characteristics

Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA.

Drug: Pegaspargase
Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization

Drug: Erwinia asparaginase
Only for patients with Pegaspargase allergy or silent inactivation.
Other Names:
  • ERWINAZE®
  • ERWINIA CHRYSANTHEMI
  • ERWINASE®

Drug: Cyclophosphamide
Standard of Care
Other Name: CYTOXAN

Drug: CYTARABINE
Standard of Care
Other Names:
  • CYTOSINE ARABINOSIDE
  • ARA-C
  • CYTOSAR®

Drug: DEXAMETHASONE
Standard of Care
Other Names:
  • DECADRON®
  • HEXADROL®,
  • DEXONE®,
  • DEXAMETH®

Drug: Dexrazoxane
Standard of Care
Other Name: Zinecard

Drug: Doxorubicin
Standard of Care
Other Name: ADRIAMYCIN®

Drug: HYDROCORTISONE
Standard of Care

Drug: LEUCOVORIN CALCIUM
Standard of Care

Drug: MERCAPTOPURINE
Standard of Care
Other Name: 6-MP

Drug: METHOTREXATE
Standard of Care

Drug: Vincristine
Standard of Care
Other Name: Oncovin

Initial Very High Risk (Initial VHR)

Any of the following are present: IKZF1 deletion, MLL (KMT2A) rearrangement, low hypodiploidy, t(17;19)

Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA.

Drug: Pegaspargase
Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization

Drug: Erwinia asparaginase
Only for patients with Pegaspargase allergy or silent inactivation.
Other Names:
  • ERWINAZE®
  • ERWINIA CHRYSANTHEMI
  • ERWINASE®

Drug: Cyclophosphamide
Standard of Care
Other Name: CYTOXAN

Drug: CYTARABINE
Standard of Care
Other Names:
  • CYTOSINE ARABINOSIDE
  • ARA-C
  • CYTOSAR®

Drug: DASATINIB
Standard of Care

Drug: DEXAMETHASONE
Standard of Care
Other Names:
  • DECADRON®
  • HEXADROL®,
  • DEXONE®,
  • DEXAMETH®

Drug: Dexrazoxane
Standard of Care
Other Name: Zinecard

Drug: Doxorubicin
Standard of Care
Other Name: ADRIAMYCIN®

Drug: ETOPOSIDE
Standard of Care
Other Name: VePesid

Drug: HYDROCORTISONE
Standard of Care

Drug: LEUCOVORIN CALCIUM
Standard of Care

Drug: MERCAPTOPURINE
Standard of Care
Other Name: 6-MP

Drug: METHOTREXATE
Standard of Care

Drug: NELARABINE
Standard of Care

Drug: Vincristine
Standard of Care
Other Name: Oncovin

Final Low Risk (Final LR)

Initial Low Risk and Low MRD (<0.0001) at first time point (Day 32)

Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:

CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, methotrexate, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).

All treatment completed 24 months from date of complete remission.

Drug: Pegaspargase
Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization

Drug: Erwinia asparaginase
Only for patients with Pegaspargase allergy or silent inactivation.
Other Names:
  • ERWINAZE®
  • ERWINIA CHRYSANTHEMI
  • ERWINASE®

Drug: CYTARABINE
Standard of Care
Other Names:
  • CYTOSINE ARABINOSIDE
  • ARA-C
  • CYTOSAR®

Drug: DEXAMETHASONE
Standard of Care
Other Names:
  • DECADRON®
  • HEXADROL®,
  • DEXONE®,
  • DEXAMETH®

Drug: HYDROCORTISONE
Standard of Care

Drug: MERCAPTOPURINE
Standard of Care
Other Name: 6-MP

Drug: METHOTREXATE
Standard of Care

Drug: Vincristine
Standard of Care
Other Name: Oncovin

Final Intermediate Risk (Final IR)

Initial High Risk and Low MRD (<0.0001) at first time point (Day 32)

Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:

CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).

All treatment completed 24 months from date of complete remission.

Drug: Pegaspargase
Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization

Drug: Erwinia asparaginase
Only for patients with Pegaspargase allergy or silent inactivation.
Other Names:
  • ERWINAZE®
  • ERWINIA CHRYSANTHEMI
  • ERWINASE®

Drug: CYTARABINE
Standard of Care
Other Names:
  • CYTOSINE ARABINOSIDE
  • ARA-C
  • CYTOSAR®

Drug: DEXAMETHASONE
Standard of Care
Other Names:
  • DECADRON®
  • HEXADROL®,
  • DEXONE®,
  • DEXAMETH®

Drug: Dexrazoxane
Standard of Care
Other Name: Zinecard

Drug: Doxorubicin
Standard of Care
Other Name: ADRIAMYCIN®

Drug: HYDROCORTISONE
Standard of Care

Drug: MERCAPTOPURINE
Standard of Care
Other Name: 6-MP

Drug: METHOTREXATE
Standard of Care

Drug: Vincristine
Standard of Care
Other Name: Oncovin

Final High Risk (Final HR)

Initial Low Risk or Initial High Risk with High MRD (>=0.0001) at first time point (Day 32) but low MRD (<0.001) at second time point (week 10-12)

Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:

CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).

All treatment completed 24 months from date of complete remission.

Drug: Pegaspargase
Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization

Drug: Erwinia asparaginase
Only for patients with Pegaspargase allergy or silent inactivation.
Other Names:
  • ERWINAZE®
  • ERWINIA CHRYSANTHEMI
  • ERWINASE®

Drug: CYTARABINE
Standard of Care
Other Names:
  • CYTOSINE ARABINOSIDE
  • ARA-C
  • CYTOSAR®

Drug: DEXAMETHASONE
Standard of Care
Other Names:
  • DECADRON®
  • HEXADROL®,
  • DEXONE®,
  • DEXAMETH®

Drug: Dexrazoxane
Standard of Care
Other Name: Zinecard

Drug: Doxorubicin
Standard of Care
Other Name: ADRIAMYCIN®

Drug: HYDROCORTISONE
Standard of Care

Drug: MERCAPTOPURINE
Standard of Care
Other Name: 6-MP

Drug: METHOTREXATE
Standard of Care

Drug: Vincristine
Standard of Care
Other Name: Oncovin

Final Very High Risk (Final VHR)

Initial VHR or any patient with high MRD (>=0.001) at second time point (week 10-12)

Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:

Consolidation IB/B-ALL (High-dose methotrexate + leucovorin, cyclophosphamide, etoposide, IT chemotherapy); Consolidation IB/T-ALL (nelararbine, cyclophosphamide, etoposide); Consolidation IC (High-dose cytarabine, etoposide, dexamethasone, pegaspargase [by direct assignment], IT chemotherapy); CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).

Dasatinib administered daily during all phases to pts with ABL1-class fusions. All treatment completed 24 months from date of complete remission.

Drug: Pegaspargase
Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization

Drug: Erwinia asparaginase
Only for patients with Pegaspargase allergy or silent inactivation.
Other Names:
  • ERWINAZE®
  • ERWINIA CHRYSANTHEMI
  • ERWINASE®

Drug: Cyclophosphamide
Standard of Care
Other Name: CYTOXAN

Drug: CYTARABINE
Standard of Care
Other Names:
  • CYTOSINE ARABINOSIDE
  • ARA-C
  • CYTOSAR®

Drug: DASATINIB
Standard of Care

Drug: DEXAMETHASONE
Standard of Care
Other Names:
  • DECADRON®
  • HEXADROL®,
  • DEXONE®,
  • DEXAMETH®

Drug: Dexrazoxane
Standard of Care
Other Name: Zinecard

Drug: Doxorubicin
Standard of Care
Other Name: ADRIAMYCIN®

Drug: ETOPOSIDE
Standard of Care
Other Name: VePesid

Drug: HYDROCORTISONE
Standard of Care

Drug: LEUCOVORIN CALCIUM
Standard of Care

Drug: MERCAPTOPURINE
Standard of Care
Other Name: 6-MP

Drug: METHOTREXATE
Standard of Care

Drug: NELARABINE
Standard of Care

Drug: Vincristine
Standard of Care
Other Name: Oncovin

Active Comparator: Fixed Dose Pegaspargase
Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks at standard fixed-dose (2500 IU/m2/dose).
Drug: Pegaspargase
Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization

Drug: Erwinia asparaginase
Only for patients with Pegaspargase allergy or silent inactivation.
Other Names:
  • ERWINAZE®
  • ERWINIA CHRYSANTHEMI
  • ERWINASE®

Experimental: Reduced Dose (PK-Adjusted) Pegaspargase
Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks beginning at a reduced dose (2000 IU/m2/dose); subsequent doses adjusted based on nadir serum asparaginase activity (NSAA) levels, with goal of maintaining NSAA between 0.4 and 1.0 IU/mL
Drug: Pegaspargase
Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization

Drug: Erwinia asparaginase
Only for patients with Pegaspargase allergy or silent inactivation.
Other Names:
  • ERWINAZE®
  • ERWINIA CHRYSANTHEMI
  • ERWINASE®

Direct Assignment
All VHR patients, and any Final LR, IR, HR patients who decline randomization: Assigned to receive standard dosing of pegaspargase (15 doses of pegaspargase every 2-weeks at standard fixed-dose; 2500 IU/m2/dose).
Drug: Pegaspargase
Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization

Drug: Erwinia asparaginase
Only for patients with Pegaspargase allergy or silent inactivation.
Other Names:
  • ERWINAZE®
  • ERWINIA CHRYSANTHEMI
  • ERWINASE®




Primary Outcome Measures :
  1. Complete Remission Rate [ Time Frame: After 1 month of treatment (Induction IA) for all participants, assessed at the end of first month of treatment in all participants through study completion (expected to take 4-5 years to accrue) ]
  2. Event-Free Survival [ Time Frame: From registration to the time of induction failure, relapse, death, or second malignancy, whichever came first, assessed up to 60 months. ]

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: From registration to the time of death from any cause, assessed up to 60 months. ]
  2. Disease Free Survival [ Time Frame: From randomization or direct assignment (for participants who achieved a complete remission and were assigned a final risk group) to the time of relapse, death, or second malignancy, whichever came first, assessed up to 60 months. ]
  3. Nadir Serum Asparaginase Activity (NSAA) [ Time Frame: During post-induction therapy with 30-weeks of pegaspargase (15 doses), collected during the first 6 months of therapy for all participants through study completion (expected to take 4-5 years to accrue) ]
    Proportion of patients receiving pegaspargase with NSAA >= 1.0 IU/mL

  4. Non-allergic Asparaginase Toxicity [ Time Frame: During post-induction therapy with 30-weeks of pegaspargase (15 doses). collected during the first 6 months of therapy for all participants through study completion (expected to take 4-5 years to accrue) ]
    Frequency of non-allergic asparaginase-related toxicities, an average of 5 years.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Confirmed diagnosis of acute lymphoblastic leukemia. Diagnosis should be made by bone marrow aspirate or biopsy demonstrating ≥ 25% involvement by lymphoblasts, with flow cytometry or immunohistochemistry confirming B-precursor or T-ALL phenotype.

    -- For patients with circulating blasts in the peripheral blood, flow cytometry confirmation of B-ALL or T-ALL phenotype is sufficient for registration onto the study. Bone marrow aspirate and/or biopsy should be performed as soon as feasible, preferably prior to the initiation of any therapy.

  2. Prior Therapy: No prior therapy is allowed except for the following:

    • Corticosteroids: Short courses of corticosteroid (defined as ≤ 7 days of corticosteroids within the 4-weeks preceding registration) are allowed prior to registration.

      --- Participants who have been on corticosteroids chronically (defined as more than 7 days of corticosteroids within the 4-weeks preceding registration or more than 28 days of corticosteroids over the preceding 6 months) are not eligible.

    • IT cytarabine: A single dose of intrathecal cytarabine (at the time of the diagnostic lumbar puncture) is allowed prior to registration. If patient has received IT cytarabine prior to registration, Day 1 IT cytarabine should not be administered.
    • Emergent Radiation Therapy: Emergent radiation to the mediastinum or other life-threatening masses is allowed prior to registration.
  3. Age: 365 days to < 22 years
  4. Direct bilirubin < 1.4 mg/dL (23.9 micromoles/L).
  5. Ability of parent or guardian to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Mature B-cell (Burkitt's) ALL (defined by the presence of surface immunoglobulin and/or the t(8;14)(q24;q32), t(8;22), or t(2;8) translocation and/or c-myc-gene rearrangement).
  2. World Health Organization diagnostic criteria of mixed phenotype acute leukemia (MPAL) or leukemia of ambiguous lineage
  3. Any chemotherapy or radiotherapy for previous malignancy are not eligible.
  4. Treatment in past with any anti-neoplastic agent, including methotrexate, 6-mercaptopurine, 6-thioguanine, vincristine cyclophosphamide, cytarabine (except for IT cytarabine), or any anthracycline, for any reason (eg, rheumatologic or autoimmune condition).
  5. Currently receiving any investigational agents.
  6. Known HIV-positivity
  7. Uncontrolled intercurrent illness including, but not limited to ongoing infection with vital sign instability (hypotension, respiratory insufficiency), life-threatening acute tumor lysis syndrome (eg, with renal failure), symptomatic congestive heart failure, cardiac arrhythmia, intracranial or other uncontrolled bleeding, or psychiatric illness/social situations that would limit compliance with study requirements.
  8. Pregnant women are excluded from this study because many of the agents used on this protocol have potential for teratogenic and/or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with these chemotherapy agents, breastfeeding should be discontinued if the mother is enrolled.
  9. History of a previous malignancy. Exception: Individuals with a previous malignancy treated with surgery only (no chemotherapy or radiotherapy) more than 5 years prior to registration may be enrolled.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03020030


Contacts
Layout table for location contacts
Contact: Lewis Silverman, MD 617-632-6191 lbsilverman@partners.org

Locations
Layout table for location information
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Lewis Silverman, MD    617-632-6191    lewis_silverman@dfci.harvard.edu   
Principal Investigator: Lewis Silverman, MD         
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Lewis Silverman, MD    617-632-6191    lewis_silverman@dfci.harvard.edu   
Principal Investigator: Lewis Silverman, MD         
United States, New Jersey
Rutgers Cancer Institute of New Jersey Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Peter Cole, MD       colepd@cinj.rutgers.edu   
Principal Investigator: Peter Cole, MD         
United States, New York
Montefiore Medical Center Recruiting
Bronx, New York, United States, 10467
Contact: Lisa Gennarini, MD       lfigueir@montefiore.org   
Principal Investigator: Lisa Gennarini, MD         
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Kara Kelly, MD       Kara.Kelly@RoswellPark.org   
Principal Investigator: Kara Kelly, MD         
Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian Recruiting
New York, New York, United States, 10032
Contact: Justine Kahn, MD       jk2034@cumc.columbia.edu   
Principal Investigator: Justine Kahn, MD         
United States, Rhode Island
Hasbro Children's Hospital / Rhode Island Hospital Recruiting
Providence, Rhode Island, United States, 02903
Contact: Jennifer Welch, MD       jwelch@lifespan.org   
Canada, Quebec
Hospital Sainte Justine, University of Montreal Recruiting
Montreal, Quebec, Canada
Contact: Thai Tran, MD       thai-hoa.tran@recherche-ste-justine.qc.ca   
Principal Investigator: Thai Tran, MD         
Centre Hospitalier U. de Quebec Recruiting
Quebec City, Quebec, Canada
Contact: Bruno Michon, MD       bruno.michon@mail.chuq.qc.ca   
Principal Investigator: Bruno Michon, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
Servier
Investigators
Layout table for investigator information
Principal Investigator: Lewis Silveman, MD Dana-Farber Cancer Institute

Layout table for additonal information
Responsible Party: Lewis B. Silverman, M.D., Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT03020030     History of Changes
Other Study ID Numbers: 16-001
First Posted: January 13, 2017    Key Record Dates
Last Update Posted: May 27, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Lewis B. Silverman, M.D., Dana-Farber Cancer Institute:
acute lymphoblastic leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Cytarabine
Dexamethasone
Dexamethasone acetate
Hydrocortisone
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Methotrexate
Etoposide
Etoposide phosphate
Vincristine
Dasatinib
Asparaginase
Mercaptopurine
Pegaspargase
Dexrazoxane
Razoxane
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents